跳至主要内容
临床试验/NCT05349630
NCT05349630尚未招募早期 1 期

Impact of Iron Supplementation on Right Ventricular Function and Exercise Performance in Hypoxia (A Sub-Study)

University of Colorado, Denver2 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2028年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
尚未招募
入组人数
5
试验地点
2
主要终点
Maximum workload

研究概览

简要总结

The purpose of this study is to determine if taking iron supplement pills improves exercise performance in low-oxygen conditions.

详细描述

Hypoxia (low oxygen) causes the blood vessels in the lungs to constrict (hypoxic pulmonary vasoconstriction). This increases the pressure (afterload) the right ventricle faces as it pumps blood to the lungs. Increased right ventricular afterload during hypoxia may compromise exercise capacity. Intravenous iron administration prior to hypoxic exposure has been shown to blunt the hypoxia-induced increase in right ventricular afterload. This may be through iron's action in the Hypoxia Inducible Factor (HIF) pathway. Iron is a cofactor for prolyl hydroxylases that degrade HIF subunits and thus may "turn off" HIF-related pathways of pulmonary artery vasoconstriction and remodeling. However, it is not known whether oral iron supplementation similarly reduces right ventricular afterload in hypoxia, or what impact iron has on right ventricular function and exercise capacity in hypoxia.

This is a human physiology study that will characterize the impact of oral iron supplementation on right ventricular function and exercise performance in hypoxia. It is a follow-up "sub-study" to a separate, "parent" study (NCT05272514) by the same investigators which evaluates resting and exertional right ventricular performance in normoxia and hypoxia in 10 healthy individuals. In this follow-up study, 5 individuals who completed the parent study will be eligible to enroll. As part of the parent study, participants will complete baseline echocardiography to assess right ventricular function and cardiopulmonary exercise testing to assess exercise performance in normoxia and hypoxia. After enrolling in this study, participants will take an oral iron supplement (ferrous sulfate 325 mg oral daily) for 30 days. They will then return for one visit. First, participants will complete submaximal exercise while breathing room air. Submaximal exercise will include 5 minutes each at 40% and 60% of baseline hypoxic (fraction of inspired oxygen [FiO2] 12%) maximal oxygen uptake (VO2max) achieved during parent study. After 10 minutes' rest, echocardiographic measurements will be obtained at upright rest with FiO2 21%, 17%, 15%, and 12% to characterize the impact of progressive hypoxia on resting right ventricular function. Participants will then repeat submaximal exercise tests at FiO2 12%, followed by a short period of recovery. Thereafter, participants will complete a symptom-limited cardiopulmonary exercise test at FiO2 12%. Measurements will include heart rate/rhythm, oxygen saturation, blood pressure, gas exchange parameters (oxygen uptake [VO2], carbon dioxide production [VCO2], and minute ventilation), rated perceived exertion and resting echocardiographic measurements.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 - 60
  • For women, premenopausal status

排除标准

  • Active cardiovascular or pulmonary disease (e.g. hypertension, coronary artery disease, cardiomyopathy, arrhythmia, valvular abnormalities, diabetes, peripheral vascular disease, tobacco use, chronic obstructive pulmonary disease, asthma, interstitial lung disease, restrictive lung disease, or pulmonary hypertension)
  • Use of cardiac- or pulmonary-related medications
  • Prior history of high altitude pulmonary edema or high altitude cerebral edema
  • Body mass index < 18.5 or > 30
  • Iron deficiency
  • Iron supplementation (oral or intravenous) in the preceding 60 days
  • Systemic anticoagulation or aspirin use that cannot be temporarily held for the study
  • Pregnancy
  • Non-cardiopulmonary disorders that adversely influence exercise ability (e.g. arthritis or peripheral vascular disease)
  • Dedicated athletic training (defined here as spending >9 hours per week in vigorous physical activity [≥6 mets])
  • Regular high-altitude exercise (defined here as engaging in vigorous physical activity [≥1 hour at ≥6 mets] at ≥8,000 ft for >2 days per week over the preceding 4 weeks)
  • Residence at ≥8,000 ft for 3 or more consecutive nights in the preceding 30 days

研究组 & 干预措施

Healthy individuals - pre-iron

Placebo Comparator

Five healthy participants will be enrolled. Baseline echocardiography and exercise data prior to oral iron supplementation will be obtained as part of the "parent" study to this study (NCT05272514).

干预措施: Ferrous sulfate 325mg (Drug)

Healthy individuals - post-iron

Active Comparator

The same five healthy participants will complete echocardiography and exercise testing after taking 30 days of oral iron supplementation.

干预措施: Ferrous sulfate 325mg (Drug)

结局指标

主要结局

Maximum workload

时间窗: Up to 1 hour

Workload in Watts at peak exercise on upright cycle ergometer

Maximal oxygen uptake

时间窗: Up to 1 hour

Maximal oxygen uptake at peak exercise (VO2max) in L/min

次要结局

  • Submaximal Stage 1 workload(Up to 1 hour)
  • Oxygen saturation at peak exercise(Up to 1 hour)
  • Pulmonary artery systolic pressure measured by echocardiography(Up to 1 hour)
  • Submaximal Stage 2 workload(Up to 1 hour)
  • Tricuspid annular plane systolic excursion measured by echocardiography(Up to 1 hour)
  • Ventilatory threshold(Up to 1 hour)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验